Literature DB >> 28427901

The 20kDa and 22kDa forms of human growth hormone (hGH) exhibit different intracellular signalling profiles and properties.

Liu Yao-Xia1, Chen Jing-Yan1, Tang Xia-Lian1, Chen Ping1, Zhang Min2.   

Abstract

Human Growth Hormone (hGH) includes two main variants. The first is 22kDa GH (22K-GH), which is predominant in the blood circulation. The second most abundant variant is 20K-GH, which makes up 5-10% of the blood circulation. Both bind and activate the same receptor, called the human growth hormone receptor (GHR). However, the reason why 22K-GH and 20K-GH exhibit similar, but not identical physiological activities remains poorly understood. In this article, the intracellular signalling profiles between these two hormones were examined. Western blot analyses were performed in 3T3-F442A and CHO cells transfected with GHR (CHO-GHR). The results revealed that both 22K-GH and 20K-GH can activate Janus kinase 2 (JAK2) and signal transducers and activators of transcription 1, 3 and 5 (STATs 1/3/5). Both induced tyrosine phosphorylation of JAK2 and STAT/1/3/5 in a time-dependent and dose-dependent manner. However, there were significant differences in the intracellular signalling properties between 22K-GH and 20K-GH. In particular, the kinetics of signalling shown by 22K-GH and 20K-GH is different. In addition, we found that the 20K-GH-induced tyrosine phosphorylation of signalling proteins was weaker than that of 22K-GH. Together, these observations indicate that the levels and kinetics of phosphorylation mediated by the main signalling proteins triggered by 22K-GH or 20K-GH were not exactly the same. This may provide a possible explanation for the different biological activities exhibited by 22K-GH and 20K-GH.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  20kDa GH; 22kDa GH; JAK2-STAT5; Signalling pathway

Mesh:

Substances:

Year:  2017        PMID: 28427901     DOI: 10.1016/j.ygcen.2017.04.010

Source DB:  PubMed          Journal:  Gen Comp Endocrinol        ISSN: 0016-6480            Impact factor:   2.822


  5 in total

1.  Effects of octreotide on autophagy markers and cell viability markers related to metabolic activity in rat pituitary tumor cells.

Authors:  Giovanni Tulipano; Andrea Giustina
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

2.  Different isoforms of growth hormone (20 kD-GH and 22 kD-GH) shows different biological activities in mesenchymal stem cell (MSC).

Authors:  Wei V Zheng; Yaqin Li; Yanwei Xu; Donghui Lu; Tao Zhou; Dezhi Li; Xianyi Cheng; Yu Xiong; Shaobin Wang; Zaizhong Chen
Journal:  Cell Cycle       Date:  2022-02-19       Impact factor: 5.173

3.  Human growth hormone proteoform pattern changes in pituitary adenomas: Potential biomarkers for 3P medical approaches.

Authors:  Biao Li; Xiaowei Wang; Chenguang Yang; Siqi Wen; Jiajia Li; Na Li; Ying Long; Yun Mu; Jianping Liu; Qin Liu; Xuejun Li; Dominic M Desiderio; Xianquan Zhan
Journal:  EPMA J       Date:  2021-03-03       Impact factor: 6.543

Review 4.  Post-Receptor Inhibitors of the GHR-JAK2-STAT Pathway in the Growth Hormone Signal Transduction.

Authors:  Maciej Wójcik; Agata Krawczyńska; Hanna Antushevich; Andrzej Przemysław Herman
Journal:  Int J Mol Sci       Date:  2018-06-22       Impact factor: 5.923

Review 5.  Growth hormone: isoforms, clinical aspects and assays interference.

Authors:  Júnia Ribeiro de Oliveira Longo Schweizer; Antônio Ribeiro-Oliveira; Martin Bidlingmaier
Journal:  Clin Diabetes Endocrinol       Date:  2018-08-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.